A laboratory owner accused of orchestrating one of the largest alleged Medicare genetic testing fraud schemes in recent years has been extradited to the United States after spending more than three years as a fugitive, federal authorities announced. Prosecutors allege that Khalid Ahmed Satary, 54, directed a nationwide operation that billed Medicare approximately $547 million for medically unnecessary cancer genetic tests, exploiting elderly beneficiaries through an extensive network of telemarketing call centers, patient recruiters, telemedicine providers, and laboratory businesses.

Satary, who has not been convicted of the charges against him, appeared in federal court in Virginia following his arrest on July 20 by unnamed regional partners in the Middle East. According to the US Department of Justice (DOJ), he was carrying a fraudulent Mexican passport under a false identity when he was taken into custody. His return to the United States marks the latest development in a years-long investigation into an alleged fraud operation that authorities say generated hundreds of millions of dollars in false Medicare claims.

Federal prosecutors have charged Satary with conspiracy to commit health care fraud, wire fraud, money laundering, and violations of federal anti-kickback laws. If convicted, some of the most serious charges carry maximum prison sentences of up to 20 years.

According to court documents and prosecutors, the alleged fraud took place between 2016 and 2019 and involved several laboratories under Satary’s control. Authorities say he operated Clio Laboratories in Georgia, Performance Laboratories in Oklahoma, and Lazarus Services in Louisiana as part of a coordinated effort to submit fraudulent claims to Medicare for expensive cancer genetic tests that were medically unnecessary.

Investigators allege that the operation relied on aggressive telemarketing campaigns and patient recruiters who targeted Medicare beneficiaries across the United States. Elderly individuals were contacted by phone or approached at health fairs and other public events, where they were encouraged to undergo genetic testing regardless of whether such tests were medically appropriate.

The government alleges that telemedicine physicians participating in the scheme routinely approved orders for cancer genetic tests without establishing........

© Blitz